menu
    • menu
    [{"orgOrder":0,"company":"Timberlyne Therapeutics","sponsor":"Connoya Biomedical Technology","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"CM313","moa":"CD-38","graph1":"Immunology","graph2":"Phase II","graph3":"Timberlyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Timberlyne Therapeutics \/ Timberlyne Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Timberlyne Therapeutics \/ Timberlyne Therapeutics"},{"orgOrder":0,"company":"Timberlyne Therapeutics","sponsor":"Abingworth","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Series A Financing","leadProduct":"CM313","moa":"CD-38","graph1":"Immunology","graph2":"Phase II","graph3":"Timberlyne Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.17999999999999999,"dosageForm":"Injection","sponsorNew":"Timberlyne Therapeutics \/ Abingworth","highestDevelopmentStatusID":"8","companyTruncated":"Timberlyne Therapeutics \/ Abingworth"}]

    Find Clinical Drug Pipeline Developments & Deals by Timberlyne Therapeutics

    Menu

    Timberlyne Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Timberlyne Therapeutics

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed

                            Timberlyne Therapeutics

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CM313

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Recipient : Connoya Biomedical Technology

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Timberlyne Launches With $180M to Develop Anti-CD38 Monoclonal Antibody

                            Details : Under the terms of the licensing agreement, Timberlyne has obtained exclusive development and commercialization rights to CM313 worldwide outside of greater China.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            January 09, 2025

                            Lead Product(s) : CM313

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Recipient : Connoya Biomedical Technology

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Timberlyne Therapeutics

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed

                            Timberlyne Therapeutics

                            U.S.A arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CM313

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Abingworth

                            Deal Size : $180.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Timberlyne Raises $180M Series A for CM313, Anti-CD38 Antibody for Unmet Needs

                            Details : The financing is intended to advance CM313, a potentially best-in-class monoclonal antibody targeting CD38, for immune thrombocytopenic purpura.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            January 09, 2025

                            Lead Product(s) : CM313

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Abingworth

                            Deal Size : $180.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth